QSPainRelief Consortium
ISB is a founding member of the QSPainRelief Consortium, a five-year, six-million-dollar pharmacological pain relief project. World-leading experts on chronic pain, pharmacology, pharmacogenomics, personalized medicine, systems biology, and in silico (computer) modeling (led by In Silico Biosciences, Inc.) joined forces in the consortium to develop a validated computational model for identifying optimal personalized combination treatments of existing medications for individual patients.
RECENT EVENTS
JULY 29, 2022
ISB conducted a Master Class at the QSPainRelief General Assembly